Eliana Z Agudelo, PA
Physician Assistant · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 3
- Since medical school
- 26 years
- Graduated 2000
Offices
3 locations · UCSF Medical Group Business Services · UCSF Dept of Surgery
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Eliana Z Agudelo’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$8,804
Medicare paid this office $8,804 for 73 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 49 | $5,729 | $95 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | $1,039 | $65 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 54 | $852 | $11 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | 12 | $288 | $18 |
Who their Medicare patients are
73 Original Medicare patients in 2024. Average age 68 · Under 65 19% · 85 and older 0% · Women 47% · Also on Medicaid 49% · Health risk score 3.68. Sicker patients than 9 in 10 peers; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 75% · Chronic kidney disease 58% · Diabetes 48% · Depression 36% · Coronary heart disease 25% · Heart failure 16% · Atrial fibrillation 16% · Cancer 15%.
The office billed $63,895, Medicare allowed $12,704 and paid $8,804; for 209 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 73 | 209 | 68 | 3.68 | $63,895 | $8,804 |
| 2023 | 59 | 88 | 66 | 3.80 | $52,245 | $7,335 |
| 2022 | 54 | 63 | 70 | 2.95 | $44,862 | $5,389 |
| 2021 | 60 | 66 | 68 | 2.71 | $45,077 | $5,909 |
| 2020 | 53 | 69 | 65 | 2.34 | $40,624 | $4,270 |
| 2019 | 55 | 65 | 65 | 2.53 | $46,281 | $4,685 |
| 2018 | 67 | 73 | 67 | 2.65 | $49,237 | $5,083 |
| 2017 | 44 | 49 | 65 | 2.83 | $30,533 | $3,631 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Long return visit (40+ min) | 49 | $5,734 | $104 |
2022: 1 service
| Long return visit (40+ min) | 49 | $4,650 | $91 |
2021: 1 service
| Long return visit (40+ min) | 48 | $4,881 | $94 |
2020: 1 service
| Long return visit (40+ min) | 34 | $3,092 | $79 |
2019: 1 service
| Long return visit (40+ min) | 38 | $3,676 | $80 |
2018: 2 services
| Long return visit (40+ min) | 50 | $3,952 | $76 |
| Return visit (30+ min) | 16 | $788 | $49 |
2017: 2 services
| Long return visit (40+ min) | 26 | $2,519 | $84 |
| Return visit (30+ min) | 15 | $875 | $58 |
Drugs they prescribed that Part D paid
$298,321
Pharmacies billed $298,321 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,031 generic and fewer than 11 brand-name prescriptions · $298,321 in drug cost · 37 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vemlidy | 31 | $73,140 | $2,359 |
| Xifaxan | 14 | $41,104 | $2,936 |
| Tacrolimus | 190 | $21,069 | $111 |
| Mycophenolate Mofetil | 202 | $17,601 | $87 |
| Ursodiol | 125 | $17,525 | $140 |
See all 20 drugs
| Vemlidy | 31 | $73,140 | $2,359 |
| Xifaxan | 14 | $41,104 | $2,936 |
| Tacrolimus | 190 | $21,069 | $111 |
| Mycophenolate Mofetil | 202 | $17,601 | $87 |
| Ursodiol | 125 | $17,525 | $140 |
| Mycophenolic Acid | 45 | $14,426 | $321 |
| Atovaquone | 22 | $8,914 | $405 |
| Entecavir | 31 | $8,306 | $268 |
| Lamivudine Hbv | 26 | $6,850 | $263 |
| Sirolimus | 30 | $4,435 | $148 |
| Cyclosporine Modified | 13 | $3,002 | $231 |
| Tenofovir Disoproxil | 14 | $597 | $43 |
| Propranolol | 13 | $578 | $44 |
| Prednisone | 106 | $573 | $5 |
| Emtricitabine-Tenofovir Disop | 12 | $545 | $45 |
| Omeprazole | 56 | $520 | $9 |
| Pantoprazole | 22 | $250 | $11 |
| Mirtazapine | 21 | $245 | $12 |
| Gabapentin | 13 | $67 | $5 |
| Sulfamethoxazole-Trimethoprim | 14 | $67 | $5 |
Year by year
| 2024 | 1,114 | 161 | None | None | $298,321 |
| 2023 | 1,032 | 153 | None | None | $325,129 |
| 2022 | 1,119 | 160 | 0% (0) | None | $327,615 |
| 2021 | 1,204 | 168 | 1% (13) | None | $420,210 |
| 2020 | 1,524 | 231 | None | 12% | $557,786 |
| 2019 | 1,609 | 219 | None | 11% | $503,832 |
| 2018 | 1,534 | 189 | None | None | $440,085 |
| 2017 | 1,084 | 163 | None | 16% | $357,741 |
| 2016 | 514 | 87 | None | 31% | $2,534,426 |
| 2015 | 783 | 88 | None | None | $5,913,697 |
| 2014 | 612 | 62 | None | 39% | $4,318,125 |
| 2013 | 495 | 47 | 0% (0) | None | $619,675 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 20 drugs
| Vemlidy | 29 | $61,481 | $2,120 |
| Tacrolimus | 160 | $45,464 | $284 |
| Atovaquone | 24 | $24,044 | $1,002 |
| Mycophenolate Mofetil | 177 | $20,948 | $118 |
| Ursodiol | 108 | $19,985 | $185 |
| Everolimus | 16 | $17,367 | $1,085 |
| Emtricitabine-Tenofovir Disop | 11 | $11,557 | $1,051 |
| Mycophenolic Acid | 30 | $9,698 | $323 |
| Sirolimus | 19 | $7,798 | $410 |
| Lamivudine Hbv | 28 | $6,920 | $247 |
| Entecavir | 25 | $6,598 | $264 |
| Cyclosporine Modified | 12 | $2,746 | $229 |
| Neoral | 13 | $1,128 | $87 |
| Nadolol | 13 | $961 | $74 |
| Prednisone | 87 | $750 | $9 |
| Omeprazole | 57 | $689 | $12 |
| Propranolol | 12 | $596 | $50 |
| Pantoprazole | 39 | $548 | $14 |
| Gabapentin | 18 | $313 | $17 |
| Sulfamethoxazole-Trimethoprim | 18 | $121 | $7 |
2022: 18 drugs
| Vemlidy | 37 | $68,764 | $1,858 |
| Tacrolimus | 200 | $49,025 | $245 |
| Ursodiol | 109 | $28,517 | $262 |
| Atovaquone | 25 | $26,725 | $1,069 |
| Mycophenolate Mofetil | 170 | $24,178 | $142 |
| Mycophenolic Acid | 50 | $20,816 | $416 |
| Zortress | 11 | $16,829 | $1,530 |
| Everolimus | 16 | $16,588 | $1,037 |
| Entecavir | 35 | $13,966 | $399 |
| Lamivudine Hbv | 31 | $10,270 | $331 |
| Sirolimus | 16 | $5,343 | $334 |
| Nadolol | 12 | $1,036 | $86 |
| Pantoprazole | 58 | $1,025 | $18 |
| Neoral | 12 | $952 | $79 |
| Omeprazole | 60 | $819 | $14 |
| Prednisone | 68 | $517 | $8 |
| Gabapentin | 41 | $373 | $9 |
| Famotidine | 11 | $181 | $16 |
2021: 23 drugs
| Vemlidy | 39 | $83,423 | $2,139 |
| Atovaquone | 32 | $39,260 | $1,227 |
| Tacrolimus | 170 | $37,578 | $221 |
| Zortress | 22 | $36,685 | $1,668 |
| Entecavir | 65 | $27,110 | $417 |
| Mycophenolate Mofetil | 190 | $22,011 | $116 |
| Ursodiol | 91 | $20,399 | $224 |
| Kristalose | 11 | $17,113 | $1,556 |
| Mycophenolic Acid | 38 | $16,278 | $428 |
| Lamivudine Hbv | 27 | $11,005 | $408 |
| Sirolimus | 13 | $4,720 | $363 |
| Neoral | 14 | $1,448 | $103 |
| Valganciclovir | 11 | $1,206 | $110 |
| Nadolol | 11 | $950 | $86 |
| Fluconazole | 13 | $859 | $66 |
| Omeprazole | 46 | $770 | $17 |
| Nifedipine Er | 18 | $730 | $41 |
| Pantoprazole | 57 | $679 | $12 |
| Prednisone | 79 | $679 | $9 |
| Gabapentin | 30 | $299 | $10 |
| Fludrocortisone Acetate | 15 | $271 | $18 |
| Famotidine | 14 | $198 | $14 |
| Furosemide | 17 | $111 | $7 |
2020: 27 drugs
| Tacrolimus | 277 | $58,383 | $211 |
| Zortress | 26 | $53,490 | $2,057 |
| Everolimus | 25 | $52,734 | $2,109 |
| Vemlidy | 26 | $45,017 | $1,731 |
| Xifaxan | 17 | $43,753 | $2,574 |
| Truvada | 21 | $40,110 | $1,910 |
| Mycophenolic Acid | 79 | $38,395 | $486 |
| Mycophenolate Mofetil | 230 | $37,464 | $163 |
| Atovaquone | 42 | $31,263 | $744 |
| Ursodiol | 91 | $26,829 | $295 |
| Entecavir | 52 | $26,787 | $515 |
| Sirolimus | 32 | $21,430 | $670 |
| Kristalose | 14 | $20,850 | $1,489 |
| Lamivudine Hbv | 37 | $14,238 | $385 |
| Tenofovir Disoproxil | 13 | $5,781 | $445 |
| Cyclosporine Modified | 19 | $5,179 | $273 |
| Prograf | 15 | $4,775 | $318 |
| Neoral | 20 | $3,104 | $155 |
| Valganciclovir | 11 | $2,416 | $220 |
| Prednisone | 139 | $1,139 | $8 |
| Omeprazole | 62 | $701 | $11 |
| Fluconazole | 15 | $587 | $39 |
| Pantoprazole | 48 | $422 | $9 |
| Gabapentin | 22 | $329 | $15 |
| Fludrocortisone Acetate | 21 | $219 | $10 |
| Sulfamethoxazole-Trimethoprim | 11 | $133 | $12 |
| Amlodipine Besylate | 27 | $119 | $4 |
2019: 24 drugs
| Zortress | 44 | $121,242 | $2,755 |
| Tacrolimus | 314 | $46,986 | $150 |
| Truvada | 22 | $40,382 | $1,836 |
| Mycophenolate Mofetil | 328 | $39,450 | $120 |
| Mycophenolic Acid | 55 | $38,731 | $704 |
| Sirolimus | 43 | $32,001 | $744 |
| Ursodiol | 80 | $28,382 | $355 |
| Vemlidy | 15 | $21,999 | $1,467 |
| Atovaquone | 24 | $21,315 | $888 |
| Entecavir | 32 | $16,112 | $503 |
| Kristalose | 11 | $15,668 | $1,424 |
| Valganciclovir | 20 | $13,397 | $670 |
| Lamivudine Hbv | 20 | $8,237 | $412 |
| Cyclosporine Modified | 29 | $5,549 | $191 |
| Tenofovir Disoproxil | 34 | $3,240 | $95 |
| Neoral | 17 | $2,508 | $148 |
| Omeprazole | 93 | $988 | $11 |
| Prednisone | 105 | $951 | $9 |
| Gabapentin | 47 | $656 | $14 |
| Propranolol | 11 | $547 | $50 |
| Pantoprazole | 41 | $429 | $10 |
| Fludrocortisone Acetate | 28 | $340 | $12 |
| Amlodipine Besylate | 21 | $90 | $4 |
| Furosemide | 18 | $74 | $4 |
2018: 25 drugs
| Zortress | 28 | $80,253 | $2,866 |
| Entecavir | 60 | $51,582 | $860 |
| Mycophenolate Mofetil | 270 | $36,291 | $134 |
| Tacrolimus | 304 | $32,926 | $108 |
| Truvada | 20 | $30,915 | $1,546 |
| Atovaquone | 21 | $28,918 | $1,377 |
| Ursodiol | 78 | $24,197 | $310 |
| Mycophenolic Acid | 37 | $20,517 | $555 |
| Sirolimus | 31 | $18,204 | $587 |
| Tenofovir Disoproxil | 24 | $11,976 | $499 |
| Lamivudine Hbv | 20 | $7,956 | $398 |
| Valganciclovir | 12 | $3,788 | $316 |
| Cyclosporine Modified | 20 | $3,443 | $172 |
| Dexilant | 12 | $3,341 | $278 |
| Lamivudine | 15 | $2,255 | $150 |
| Esomeprazole Magnesium | 12 | $1,633 | $136 |
| Prednisone | 142 | $1,471 | $10 |
| Gengraf | 13 | $1,235 | $95 |
| Omeprazole | 111 | $1,139 | $10 |
| Gabapentin | 44 | $726 | $17 |
| Acyclovir | 11 | $422 | $38 |
| Pantoprazole | 27 | $367 | $14 |
| Fludrocortisone Acetate | 35 | $355 | $10 |
| Amlodipine Besylate | 20 | $82 | $4 |
| Furosemide | 14 | $81 | $6 |
2017: 21 drugs
| Entecavir | 38 | $41,899 | $1,103 |
| Tacrolimus | 195 | $30,102 | $154 |
| Mycophenolic Acid | 28 | $29,972 | $1,070 |
| Truvada | 17 | $26,861 | $1,580 |
| Viread | 23 | $24,935 | $1,084 |
| Atovaquone | 17 | $23,431 | $1,378 |
| Mycophenolate Mofetil | 190 | $22,430 | $118 |
| Myfortic | 12 | $12,757 | $1,063 |
| Ursodiol | 33 | $12,138 | $368 |
| Budesonide Ec | 11 | $11,371 | $1,034 |
| Sirolimus | 14 | $10,745 | $768 |
| Lamivudine | 14 | $3,149 | $225 |
| Gengraf | 12 | $1,247 | $104 |
| Prednisone | 100 | $1,136 | $11 |
| Omeprazole | 89 | $939 | $11 |
| Gabapentin | 26 | $326 | $13 |
| Fludrocortisone Acetate | 26 | $259 | $10 |
| Diphenoxylate-Atropine | 11 | $156 | $14 |
| Furosemide | 27 | $95 | $4 |
| Sulfamethoxazole-Trimethoprim | 18 | $76 | $4 |
| Amlodipine Besylate | 11 | $44 | $4 |
2016: 15 drugs
| Sovaldi | 29 | $809,537 | $27,915 |
| Harvoni | 23 | $726,928 | $31,606 |
| Daklinza | 29 | $607,385 | $20,944 |
| Procrit | 22 | $86,053 | $3,911 |
| Xifaxan | 15 | $22,071 | $1,471 |
| Tacrolimus | 66 | $7,951 | $120 |
| Lamivudine Hbv | 20 | $3,544 | $177 |
| Ribavirin | 51 | $3,248 | $64 |
| Mycophenolate Mofetil | 23 | $2,002 | $87 |
| Prednisone | 26 | $223 | $9 |
| Omeprazole | 17 | $177 | $10 |
| Gabapentin | 19 | $160 | $8 |
| Pantoprazole | 16 | $159 | $10 |
| Furosemide | 14 | $66 | $5 |
| Citalopram Hbr | 12 | $48 | $4 |
2015: 22 drugs
| Harvoni | 113 | $3,519,001 | $31,142 |
| Sovaldi | 39 | $1,051,324 | $26,957 |
| Daklinza | 22 | $466,263 | $21,194 |
| Olysio | 17 | $376,999 | $22,176 |
| Viekira Pak | 12 | $327,891 | $27,324 |
| Procrit | 21 | $80,008 | $3,810 |
| Xifaxan | 25 | $32,105 | $1,284 |
| Ribavirin | 75 | $8,724 | $116 |
| Tacrolimus | 38 | $5,307 | $140 |
| Nexium | 12 | $3,451 | $288 |
| Mycophenolate Mofetil | 30 | $2,013 | $67 |
| Ribasphere | 16 | $1,804 | $113 |
| Omeprazole | 34 | $298 | $9 |
| Prednisone | 29 | $228 | $8 |
| Gabapentin | 30 | $202 | $7 |
| Pantoprazole | 16 | $196 | $12 |
| Pravastatin | 13 | $169 | $13 |
| Nifedical Xl | 13 | $137 | $11 |
| Sulfamethoxazole-Trimethoprim | 19 | $92 | $5 |
| Furosemide | 17 | $44 | $3 |
| Citalopram Hbr | 19 | $36 | $2 |
| Metoprolol | 18 | $28 | $2 |
2014: 19 drugs
| Sovaldi | 79 | $2,244,050 | $28,406 |
| Olysio | 50 | $1,129,975 | $22,600 |
| Harvoni | 23 | $737,211 | $32,053 |
| Procrit | 37 | $134,457 | $3,634 |
| Xifaxan | 18 | $26,596 | $1,478 |
| Mycophenolic Acid | 11 | $5,670 | $515 |
| Ribasphere | 37 | $5,566 | $150 |
| Mycophenolate Mofetil | 26 | $3,874 | $149 |
| Tacrolimus | 22 | $3,269 | $149 |
| Cyclosporine Modified | 13 | $2,318 | $178 |
| Ribavirin | 18 | $1,635 | $91 |
| Pantoprazole | 17 | $697 | $41 |
| Ondansetron | 13 | $397 | $31 |
| Escitalopram | 13 | $318 | $24 |
| Omeprazole | 30 | $302 | $10 |
| Prednisone | 20 | $157 | $8 |
| Sulfamethoxazole-Trimethoprim | 27 | $152 | $6 |
| Citalopram Hbr | 23 | $144 | $6 |
| Amlodipine Besylate | 12 | $62 | $5 |
2013: 16 drugs
| Procrit | 50 | $215,795 | $4,316 |
| Pegasys | 39 | $111,489 | $2,859 |
| Victrelis | 13 | $71,399 | $5,492 |
| Neupogen | 13 | $22,426 | $1,725 |
| Myfortic | 13 | $16,390 | $1,261 |
| Ribavirin | 21 | $4,652 | $222 |
| Mycophenolate Mofetil | 17 | $2,148 | $126 |
| Tacrolimus | 18 | $1,259 | $70 |
| Ondansetron | 12 | $785 | $65 |
| Bupropion Hcl Sr | 12 | $498 | $41 |
| Sulfamethoxazole-Trimethoprim | 54 | $268 | $5 |
| Omeprazole | 26 | $230 | $9 |
| Citalopram Hbr | 17 | $119 | $7 |
| Prednisone | 19 | $108 | $6 |
| Amlodipine Besylate | 15 | $102 | $7 |
| Ciprofloxacin | 19 | $81 | $4 |
Professional record
- NPI
- 1982646386
- Licence
- CA PA16864
- Group
- UCSF Medical Group Business Services · UCSF Dept of Surgery
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00PA168640
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 1635 Divisadero Street, Suite 625, Box 1821, San Francisco, CA, 94143
- NPI first listed
- 2006-06-11
- NPI last updated
- 2007-07-09
This is when the NPI record was last certified, not a medical board exam.